Vanderbilt University Medical Center | Strategic Alliance Partners

“[We] found that women were spending on average, nearly $35 a week on incontinence products in the highest symptom severity, which is a huge financial burden,” says Elisabeth M. Sebesta, MD.

Amy N. Luckenbaugh, MD, recaps 5 presentations from the 2022 American Society of Clinical Oncology Annual Meeting.

"Now with FDA approval, patients will have much improved ability to use this efficacious therapy on a long-term basis, which is most beneficial for them," Roger R. Dmochowski, MD, MMHC.

“To have at the 2-year mark basically half the patients still without evidence of disease is really a step forward,” says Sam S. Chang, MD, MBA.

“We're doing probably one of the highest volume of HoLEP cases…in the United States,” says Nicole L. Miller, MD, FACS.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Kelvin A. Moses, MD, PhD, discusses the prostate cancer immunotherapy treatment sipuleucel-T (Provenge).

“In using an immune therapy approach, and using your own cells, it's very innovative in the mechanism that it works,” says Kelvin A. Moses, MD, PhD.

Tosoian is developing the Contemporary Uro-oncologic specimens and Protocols (CUSP) program, which will implement prospective collection of the biospecimens and correlative clinical data essential to basic, translational, and clinical genitourinary cancer research.

“I think we are good at treating the cancer but maybe not great at treating the patient as a whole. And that is an area that we can improve going forward based on research like this,” says Amy N. Luckenbaugh, MD.

“We kind of expected that treatment type wouldn't make a ton of difference in terms of…mental health outcomes after either surgery or radiation…but we were very clearly able to find groups of people who were at risk for poor mental health outcomes,” says Amy N. Luckenbaugh, MD.

In this installment of Urology Times' 50th Anniversary Innovation Celebration, Sam S. Chang, MD, MBA, discusses the critical role that BCG has played in managing bladder cancer, and how the BCG shortage continues to evolve.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Melissa R. Kaufman, MD, PhD, FACS, discusses the significance of onabotulinumtoxinA treatment in patients with overactive bladder.

"There have been few therapies that have so galvanized management of a urologic condition as what we've witnessed over the past decade regarding the use of onabotulinumtoxinA (Botox) for bladder dysfunction," says Melissa R. Kaufman, MD, PhD, FACS.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Melissa R. Kaufman, MD, PhD, FACS, discusses the innovative use of stem cell–derived treatments in urologic conditions such as stress urinary incontinence.

"The newest frontier of therapy for stress incontinence is regenerative medicine and stem cell–based therapies," says Melissa R. Kaufman, MD, PhD, FACS.

In this interview, Kelvin A. Moses, MD, PhD, FACS, provides insight on how clinicians may be able to help patients with prostate cancer address the financial burden of the disease.

“In non–muscle-invasive bladder cancer, we need more biomarkers, something that can hopefully reduce the frequency of invasive procedures for these patients,” says Kristen Scarpato, MD, MPH.

"I'm hopeful and optimistic that over the next couple of years, we have some really reliable biomarkers to utilize in these patients who we know have frequent recurrences,"says Kristen Scarpato, MD, MPH.

“We want to make sure that if it is an efficacious medicine for that patient to consider using a generic formulation,” says Kelvin A. Moses, MD, PhD, FACS.

“We need to be aware of what patients are having to pay out of pocket, how it can impact their overall quality of life, [and] how can it impact their ability to pay for other necessities in life,” says Kelvin A. Moses, MD, PhD, FACS.

“[I focused on] why this such an important topic and how we might better counsel our patients,” says Kristen Scarpato, MD, MPH.

Benefits include improved quality of life and symptom management.

Multiple investigational agents have been developed and are being studied.

"There are going to be more trials open for those patients who may not have received BCG...I think that's essential, to realize that there are other treatments on the horizon for patients with non–muscle-invasive bladder cancer," says Sam S. Chang, MD.

“I wouldn't be surprised if we have spotty distribution areas of concern for the next several years,” says Sam S. Chang MD, MBA, on the latest episode of the UT podcast Speaking of Urology.

Nicole L. Miller, MD, FACS, discusses studies involving ultrasonic propulsion to facilitate clearance of fragments, dusting vs basketing, and more.

In this interview, Melissa R. Kaufman, MD, PhD, FACS, describes the promise of a regenerative approach to treating recurrent incontinence in women known as autologous muscle derived cells for urinary sphincter repair (AMDC-USR).

These compensatory behaviors are associated with more severe urinary symptoms and higher anxiety and stress.

“[These patients] have very limited treatment options and the adult muscle derived cells for sphincter regeneration represent a non-surgical means to provide very durable and effective support for these women who have suffered mightily from stress incontinence, oftentimes for long periods of time,” says Melissa R. Kaufman, MD, PhD, FACS.

“This technology is truly a transformational opportunity for urology,” says Melissa R. Kaufman, MD, PhD, FACS.